Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma
NCT07128680Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of exl01 in renal cell carcinoma (RCC) (2 arms), sponsored by City of Hope. Primary endpoint: Change in plasma IFNγ at 13 weeks. Started Mar 2026; status: recruiting.
02
Drugs
exl01
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07128680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128680.